HIV Vaccine Trials Network
|Industry||HIV Vaccine Research|
|Key people||Lawrence Corey, Lead PI|
The HIV Vaccine Trials Network (HVTN) is a non-profit organization which connects physicians and scientists with activists and community educators for the purpose of conducting clinical trials seeking a safe and effective HIV vaccine. Collaboratively, research professionals and laypeople review potential vaccines for safety, immune response, and efficacy. The HVTN is the only HIV vaccine research network sponsored nationwide by the American government. It also manages the only large-scale HIV vaccine research trial network in Africa.
The HVTN collaborates with the Division of Acquired Immunodeficiency Syndrome (DAIDS). Funding comes from the National Institute of Allergy and Infectious Diseases and National Institutes of Health, which oversee DAIDS. HVTN is headquartered at the Fred Hutchinson Cancer Research Center in Seattle. The vaccines being tested come from various producers, both commercial and non-profit. The HVTN is a network for testing vaccines, and while its members may also work in vaccine development for other entities, the mission of the HVTN does not include vaccine design.
Typically, researchers conduct clinical research on human subjects by asking volunteers to give informed consent to participate in an experiment by taking drugs that have not always been proven safe or effective in humans, though their safety has been tested (usually in animals) prior to any human trials. At the HVTN, many current vaccine studies are using products with a safety record that has been established in previous human trials.
The Nuremberg Code, the Declaration of Helsinki, and the Belmont Report are legal documents written in layman's terms which local governments use to model their laws for establishing rules for conducting clinical trials, and all contemporary clinical trials of international worth follow all the rules set by these precedents.
However, HIV vaccine research requires more than just these protections, and because of this, from the inception of their research the HVTN has instituted a "community advisory board" (CAB) system in addition to the usual controls. The CAB is similar to an Institutional Review Board (IRB) in that the researchers facilitate the granting of public data to both entities, but the difference is that the IRB consists of a professional ethics committee and the CAB consists of any community member who wants to supervise the safety, ethics, efficacy, or any other aspect of the research.
The researchers of the HVTN deemed the creation of the CAB necessary for HIV vaccine research when it has not been necessary for other clinical research because the HIV epidemic is especially urgent, new research techniques are available now that did not exist before recent major advances in genetic engineering, the public is generally overly-willing to volunteer to receive experimental vaccines for this cause, and yet the educational infrastructure already in place to disseminate information about the inherent risk in participating in vaccine research is lacking in society. For too many reasons, there is no precedent for research of this sort on this scale, and without integrating educational programs about this research into existing community institutions, the HVTN simply could not educate people to the required level to make such a fast-moving, expensive, inherently non-commercial research project possible.
African HIV vaccine research trials
In 2003 the HVTN partnered with Harvard University in establishing a small-scale vaccine trials unit in Botswana. A major reason for this project was gathering data about the prevalence of HIV in Africa and assessing the feasibility of getting grassroots support for vaccine trials in non-American culture.
In 2007 HVTN started the first large-scale HIV vaccine trials in Africa, with financial assistance from the SA Aids Vaccine Initiative. These studies will last until 2011 and include up to 3000 participants.
STEP was the name for a double-blind randomized controlled trial managed by the HVTN. It was thoroughly reviewed when a greater number of participants in the experimental group contracted HIV than the participants in the control group. The vaccine contained no HIV and no one could have contracted HIV from the vaccine, but there was intense discussion as to whether the vaccine could have increased anyone's risk of contracting HIV. Because the study was stopped early, it probably will never be possible to determine why more participants in the experimental group contracted HIV, but various theories have been proposed.
On October 1, 2009, the HVTN began a new clinical trial called HVTN 505. HVTN 505 is a project to examine whether a particular DNA prime/boost vaccine regimen will reduce viral load in individuals who later become infected with HIV. The experimental vaccine used in this study was developed by the Vaccine Research Center at the National Institutes of Health (NIH). Study organizers do not expect that this vaccine will prevent HIV infection and thus this vaccine is not planned for licensing, but it is expected to cause a response that will help researchers decide how to direct future vaccine trials.
- "About the HVTN". HVTN Website. Retrieved 2008-10-29.
- "FHCRC Named as Core Operations Center for Worldwide HVTN". FHCRC Press Release. 2000-05-25. Retrieved 2008-10-29.[dead link]
- "Current Vaccine Trials". HVTN Website. Retrieved 2008-10-29.
- "Community Advisory Board (CAB)". HVTN Website. Retrieved 2008-10-29.
- "Building a vaccine legacy on trust". FHCRC Center News. 2005-02-03. Retrieved 2008-10-29.
- "Joining a Community Advisory Board". The Body. 2003-12-20. Retrieved 2008-10-29.
- "Harvard AIDS Institute Helps Launch HIV Vaccine Trial in Botswana". Harvard Public Health NOW. 2003-08-08.
- "Africa's First Large-Scale HIV Vaccine Study Launches". Medical News Today. 2007-02-09. Retrieved 2007-03-08.
- "Volunteers join HIV vaccine trial". IOL. Retrieved 2007-03-08.
- "Africa's First Large-Scale HIV Vaccine Study Launches". Medical News Today. 2007-02-09. Retrieved 2008-10-29.
- "Status of NIAID Adenovirus-based Vaccine Studies". NIAID. Retrieved 2008-10-29.[dead link]
- Matthew S. Bajko (2009-10-01). "New trial of HIV vaccine in gay men begins". Bay Area Reporter.
- "The HVTN 505 Study Its Role in Helping Fight AIDS" (Press release). HVTN.org. 2009-10-01. Retrieved 2009-11-21.
- HIV Vaccine Trials Network
- Hope Takes Action
- Fred Hutchinson Cancer Research Center
- Division of Acquired Immunodeficiency Syndrome, NIH